Table 3.
Current Glucagon-Like Peptide 1 Receptor (GLP-1R) Agonists Used in Type 2 Diabetes Therapy
| GLP-1R Agonist Generic Name (Trade Name) | Dosing | Half-Life | Administration Required Before Meals? |
|---|---|---|---|
| Short-acting | |||
| Exenatide (Byetta) | Twice daily | 2.4 hours | Yes |
| Lixisenatide (Lyxumia) | Once-daily | 4 hours | Yes |
| Intermediate-acting | |||
| Liraglutide (Victoza) | Once-daily | 12 hours | No |
| Long-acting | |||
| Exenatide-LAR (Bydureon) | Once weekly | 96 hours | No |
| Albiglutide (Tanzeum)* | Once weekly | 6–8 days | No |
| Dulaglutide (Trulicity) | Once weekly | 90 hours | No |
| Semaglutide (Ozempic) | Once weekly | 165–184 hours | No |
Notes: Adapted with permission from Reed J, Bain S, Kanamarlapudi V. Recent advances in understandingthe role of glucagon-like peptide 1. F1000Research. 2020;9:239.257 *This product was globally withdrawn in July 2018 for commercial reasons.